(3,4,5-trimethyl-1H-pyrazol-1-yl)acetonitrile | 1170293-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (3,4,5-trimethyl-1H-pyrazol-1-yl)acetonitrile
• 英文别名: 2-(3,4,5-trimethylpyrazol-1-yl)acetonitrile
• CAS: 1170293-23-8
• 化学式: C₈H₁₁N₃
• mdl: MFCD12026945
• 分子量: 149.19
• InChiKey: HVBKGGRSRZGILP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.6
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

文献信息

• HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
  申请人：Bunnage Mark Edward

  公开号：US20130196952A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物，以及用于制备含有这些衍生物的组合物的中间体的制备过程和使用。根据本发明的化合物在许多与ALK蛋白有关或抑制ALK活性可能产生益处的疾病中非常有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• [EN] EZH2 INHIBITOR AND USE THEREOF<br/>[FR] INHIBITEUR D'EZH2 ET SON UTILISATION<br/>[ZH] EZH2抑制剂及其用途
  申请人：PHARMABLOCK SCIENCES NANJING INC

  公开号：WO2020224607A1

  公开（公告）日：2020-11-12

  本申请提供一种由式(I)表示的化合物，或其药学上可接受的盐、酯、前药、络合物、溶剂化物、水合物或异构体；以及其用于制备用于治疗EZH2介导的疾病的药物的用途。
• US8916593B2
  申请人：——

  公开号：US8916593B2

  公开（公告）日：2014-12-23
• [EN] HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES DESTINÉS AU TRAITEMENT DE MALADIES
  申请人：PFIZER

  公开号：WO2011138751A2

  公开（公告）日：2011-11-10

  The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.